Medical News

How Does Erdosteine Perform in Combination with Antibiotics?

1. 11. 2022 Source: Cough Therapy

Erdosteine is an oral mucoactive drug that reduces mucus viscosity by degrading disulfide bonds in the mucin polymer. It achieves this effect through a free thiol group in its main active metabolite, N-thiodiglycolyl-homocysteine. In addition to its mucolytic action, erdosteine exhibits antioxidant and anti-inflammatory effects and reduces bacterial adhesion, thereby enhancing the effectiveness of certain antibiotics. We provide a summary of study results demonstrating its effect on enhancing the efficacy of drugs administered in the treatment…

Benefit of Adding Erdosteine to Maintenance Treatment of COPD

Erdosteine is a mucoactive drug with anti-inflammatory, antioxidant, and anti-adhesive effects against bacteria, commonly used in the treatment of chronic obstructive pulmonary disease (COPD). In…

1. 11. 2022 Source: Cough Therapy

ERS 2022: What Insights Do Studies Focused on COPD Biomarkers Bring?

In this year's scientific program of the international congress of the European Respiratory Society (ERS 2022), there was also a lot of talk about the investigation of biomarkers of chronic…

1. 11. 2022 Source: Cough Therapy

Specific treatment of pulmonary involvement in patients with AAT deficiency −⁠ why, how, and for whom?

For patients with emphysema and decreased lung function due to alpha-1-antitrypsin deficiency (AATD), there is an approved specific treatment which involves the i.v. administration of…

1. 11. 2022 Source: Deficiency of Alpha-1-Antitrypsin

Diagnosis of AAT Deficiency According to Italian Recommendations and a Clear Algorithm for Practice

Alpha-1 antitrypsin deficiency (AATD) is a genetic disorder that primarily affects the lungs and liver. It is considered a rare disease, but it is also significantly underdiagnosed. Given the…

1. 11. 2022 Source: Deficiency of Alpha-1-Antitrypsin

Does adding statins to DOACs reduce the risk of major bleeding in patients with non-valvular atrial fibrillation?

A large retrospective study, the results of which were recently published, investigated to what extent the concurrent administration of statins is associated with a lower risk of major bleeding,…

1. 11. 2022 Source: Anticoagulant Treatment

ESC 2022: Evidence of SGLT2i Effectiveness in HFrEF Treatment is Growing: How to Integrate Them into Routine Practice?

Although the need for pharmacotherapeutic options for patients with heart failure with reduced left ventricular ejection fraction (HFrEF) is essential, challenges in implementing this medication…

1. 11. 2022 Source: Heart Failure

What Can We Expect from Sorafenib in the Treatment of Liver Cancer Affected by Nonalcoholic Fatty Liver Disease?

Ubiquitous and increasingly common obesity is a risk factor for many cancers. Over the past 20 years, studies have linked obesity to higher incidences of breast and colorectal cancers, as well as…

31. 10. 2022 Source: Oncological Treatment

Alopecia Areata –⁠ Autoimmune Inflammatory Disease and a New Targeted Treatment Option

Alopecia areata (AA) is one of the non-scarring focal alopecias. It is an autoimmune disease of the hair follicle, the etiopathogenesis of which is not entirely understood. At the hair root, a…

31. 10. 2022 Source: Biological Treatment

Contact Dermatitis in Patients with Venous Ulcers –⁠ and How to Prevent It?

The prevalence of chronic wounds increases with the rising average age, and for example, venous ulcers affect up to 2% of the global population. Materials used for wound coverage, however, present a…

31. 10. 2022 Source: Wound Healing

Prim. Václava Adámková: People mistakenly believe that there are enough antibiotics and that they will always handle infections

According to the World Health Organization (WHO), by 2050, infections untreatable with antibiotics could become the leading cause of death, surpassing cardiovascular and oncological diseases. Rising…

26. 10. 2022 Source: Anti-Infectives

EMPATHY Questionnaire as a Tool for Better Personalization of Levothyroxine Doses in Patients with Primary Hypothyroidism?

The therapy for hypothyroidism consists of substitution with levothyroxine (L-T4). Failure to achieve the target thyrotropin hormone (TSH) level can be due to non-compliance (in 60% of cases) or…

25. 10. 2022 Source: Thyroid Disorders

1 … 40 41 42 43 44 … 111

Back Filter by speciality

Remove filters

Medical News

How Does Erdosteine Perform in Combination with Antibiotics?

Benefit of Adding Erdosteine to Maintenance Treatment of COPD

ERS 2022: What Insights Do Studies Focused on COPD Biomarkers Bring?

Specific treatment of pulmonary involvement in patients with AAT deficiency −⁠ why, how, and for whom?

Diagnosis of AAT Deficiency According to Italian Recommendations and a Clear Algorithm for Practice

Does adding statins to DOACs reduce the risk of major bleeding in patients with non-valvular atrial fibrillation?

ESC 2022: Evidence of SGLT2i Effectiveness in HFrEF Treatment is Growing: How to Integrate Them into Routine Practice?

What Can We Expect from Sorafenib in the Treatment of Liver Cancer Affected by Nonalcoholic Fatty Liver Disease?

Alopecia Areata –⁠ Autoimmune Inflammatory Disease and a New Targeted Treatment Option

Contact Dermatitis in Patients with Venous Ulcers –⁠ and How to Prevent It?

Prim. Václava Adámková: People mistakenly believe that there are enough antibiotics and that they will always handle infections

Options for Tapering TPO-RA in ITP Patients: Practical Experience and Expert Consensus

Newer Beta Blockers Offered for Use in Atherosclerosis Prevention

Will up-titration or combination with bisoprolol help to better control hypertension in amlodipine users?

EMPATHY Questionnaire as a Tool for Better Personalization of Levothyroxine Doses in Patients with Primary Hypothyroidism?